C4 therapeutics to present new preclinical data on highly selective orally bioavailable bidac™ degraders at the american association for cancer research annual meeting 2024

Cft1946 data demonstrates promising single agent and combination activity in preclinical models of braf v600x melanoma, colorectal cancer, non-small cell lung cancer and brain metastasis cft1946 data demonstrates promising single agent and combination activity in preclinical models of braf v600x melanoma, colorectal cancer, non-small cell lung cancer and brain metastasis
CCCC Ratings Summary
CCCC Quant Ranking